NervGen doses first participant in Phase 3 RESTORE trial of NVG-291 for chronic spinal cord injury

PUBT · 1d ago
NervGen doses first participant in Phase 3 RESTORE trial of NVG-291 for chronic spinal cord injury
  • NervGen began dosing in RESTORE, a Phase 3 registrational trial of NVG-291 in chronic cervical motor-incomplete spinal cord injury.
  • Prior results were presented from the earlier placebo-controlled CONNECT SCI study, which showed functional improvements that informed RESTORE’s design.
  • RESTORE targets better hand function and quality of life, aiming to support greater independence rather than reporting technical performance measures.
  • Enrollment is expected to finish in H2 2027, with topline results planned for H1 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.